Showing results (21-30 of 61) with videos related to
Sort By:
Pageof 7
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 20, 2008
Natural history of osteonecrosis of the jaw in patients with multiple myelomaAshraf Badros, Evangelos Terpos, Eirini Katodritou, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2002
Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioningAshraf Badros, Bart Barlogie, Eric Siegel, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2019
A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström MacroglobulinemiaIrene M Ghobrial, Ravi Vij, David Siegel, et al.British Journal of Haematology|February 14, 2002
Predicting long-term (> or = 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplantsGuido Tricot, Trey Spencer, Jeffrey Sawyer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2014
Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myelomaKyriakos P Papadopoulos, David S Siegel, David H Vesole, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 3, 2012
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomibZhengping Wang, Jinfu Yang, Christopher Kirk, et al.Clinical Lymphoma, Myeloma & Leukemia|January 23, 2016
Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib StudyJesus Berdeja, Sundar Jagannath, Jeffrey Zonder, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2015
Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK StudyNoopur Raje, Robert Vescio, Charles W Montgomery, et al.Blood|May 3, 2017
Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myelomaAshraf Badros, Elizabeth Hyjek, Ning Ma, et al.British Journal of Haematology|October 28, 2017
A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study resultsAndrew Spencer, Simon Harrison, Jeffrey Zonder, et al.Pageof 7